Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|4|530-536

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.4, 2014-02, pp. : 530-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1695-1701

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3826-3835

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 1, 2018-01 ,pp. : e31-e32

John Wiley & Sons Inc

Access to resources Recommend Favorite

The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition

By  

CANCER, Vol. 120, Iss. 20, 2014-10 ,pp. : 3142-3153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3821-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite